This study will be a double-blind, randomized, placebo-controlled, parallel-group, multicentre trial, involving tertiary intensive care units with expertise in management of patients with decompensated cirrhosis.
Patients who satisfy inclusion criteria and do not present any of the exclusion criteria at ICU admission will be randomized into two groups:
>>Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
>>Group B: placebo treatment in addition to standard treatment (= placebo group)
Regarding the primary objetive:
To determine whether low doses of hydrocortisone improves the 28-day mortality when added to the standard management of cirrhotic patients with vasopressor dependent shock and suspicion of active infection.